We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A novel polymorphism in the 17β-hydroxysteroid dehydrogenase type 5 (aldo-keto reductase 1C3) gene is associated with lower serum testosterone levels in caucasian men.
- Authors
Jakobsson, J.; Palonek, E.; Lorentzon, M.; Ohlsson, C.; Rane, A.; Ekström, L.
- Abstract
Genetic variation in the androgen metabolizing enzymes is important to identify and feature as they may influence the risk of prostate cancer and help clarify the etiology of the disease. Human 17β-hydroxysteroid dehydrogenase type 5 (AKR1C3) is highly expressed in the prostate gland and plays a major role in the formation and metabolism of androgens. We identified five novel polymorphisms in the AKR1C3 gene. One of those an A>G substitution in exon 2 that confers a Glu77Gly change occurred in 4.8% in Caucasians but was completely absent in Orientals. Interestingly, the testosterone level in serum was significantly lower in subjects with the Gly77 allele. A promoter A>G polymorphism was associated with significantly altered promoter activity in reporter constructs, but was not associated with any change in testosterone levels. In conclusion, the Glu77Gly polymorphism is associated with lower testosterone levels in serum.The Pharmacogenomics Journal (2007) 7, 282–289; doi:10.1038/sj.tpj.6500419; published online 19 September 2006
- Subjects
GENETIC polymorphisms; ENZYMES; ANDROGENS; PROSTATE cancer; TESTOSTERONE; PHARMACOGENOMICS
- Publication
Pharmacogenomics Journal, 2007, Vol 7, Issue 4, p282
- ISSN
1470-269X
- Publication type
Article
- DOI
10.1038/sj.tpj.6500419